Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 1 Completed 30 enrolled Centre Antoine Lacassagne

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of gemcitabine given together with capecitabine and erlotinib in treating patients with advanced pancreatic cancer.

Timeline

Start: 2008-05
Primary completion: 2009-09
Completion: 2009-10

Publications

Results Francois E, Bennouna J, Chamorey E, Etienne-Grimaldi MC, Renee N, Senellart H, Michel C, Follana P, Mari V, Douillard JY, Milano G. Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. Chemotherapy. 2012;58(5):371-80. doi: 10.1159/000343969. Epub 2012 Dec 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1660 mg/m2	Oral
Subject	Erlotinib	Small molecule	50 mg	Oral
Subject	Erlotinib	Small molecule	75 mg	Oral
Subject	Erlotinib	Small molecule	100 mg	Oral
Subject	Erlotinib	Small molecule	125 mg	Oral
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Summary

Timeline

Publications

Drugs

Indications